Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery

Launched by SAINT PETERSBURG STATE UNIVERSITY, RUSSIA · Jul 8, 2024

Keywords

ClinConnect Summary

The PRIORITY trial is studying whether using special medications called fibrinolysis inhibitors during and after heart surgery can reduce the need for blood transfusions after the surgery. These medications help control blood clotting, which may help patients recover better by minimizing blood loss. The trial is taking place in multiple hospitals and is currently recruiting participants.

To be eligible for this trial, hospitals must perform at least 250 open heart surgeries each year, and the majority of doctors at these hospitals need to agree to use the fibrinolysis inhibitors as part of the treatment plan. If you or a loved one is undergoing heart surgery in a participating hospital, you may be able to join this study. Participants can expect to receive either the standard treatment or the new approach involving the fibrinolysis inhibitors, and the goal is to find out which method helps patients more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A hospital that performs a minimum of 250 open heart interventions per year.
• • 2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol).
• Exclusion Criteria:
• • Hospital does not meet inclusion criteria